Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug 11;5(1):149.
doi: 10.1038/s41392-020-00267-8.

Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma

Ruining Gong  1 , He Ren  2
Affiliations
Comment

Targeting chemokines/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma

Ruining Gong et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The interaction between immune and cancer cells and their targeting inhibitors to treat pancreatic ductal adenocarcinoma (PDAC). Pancreatic cancer cells secrete cytokines and chemokines to recruit stromal cells including myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs) and pancreatic stellate cells (PSCs). Immune checkpoint inhibitors (ICI) including anti-PD-1/PD-L1 and anti-CTLA-4. Targeting chemokines/chemokine receptors like the CCL5/CCR5 and CXCL12/CXCR4 axis facilitates the immunotherapy of pancreatic ductal adenocarcinoma
See this image and copyright information in PMC

Comment on

References

    1. Bockorny B, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat. Med. 2020 doi: 10.1038/s41591-020-0880-x. - DOI - PubMed
    1. Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 2020 doi: 10.1038/s41571-020-0363-5. - DOI - PMC - PubMed
    1. Wang-Gillam A, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–557. doi: 10.1016/S0140-6736(15)00986-1. - DOI - PubMed
    1. Humphris JL, et al. Hypermutation in pancreatic cancer. Gastroenterology. 2017;152:68–74. doi: 10.1053/j.gastro.2016.09.060. - DOI - PubMed
    1. Wang X, et al. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Sig Transduct. Target Ther. 2020;5:38. doi: 10.1038/s41392-020-0144-8. - DOI - PMC - PubMed

Publication types